FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

NCT02485834 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-01-20

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread past the stomach and is not responding to the usual treatment. PET scans are a different way to take pictures of cancer and can be used to look at how much energy (such as glucose) is being used by the cancer. Using PET scans early to monitor the success of treatment may allow doctors to measure response and change treatment accordingly.

Conditions

  • Adenocarcinoma of the Gastroesophageal Junction
  • Gastric Adenocarcinoma
  • Gastric Cancer

Interventions

PROCEDURE

FDG-PET

PROCEDURE

surgery

DRUG

5-FU

200 mg/m\^2/day IV

DRUG

capecitabine

oral 800 mg/m\^2 BID

DRUG

docetaxel

30 mg/m\^2 IV

DRUG

Irinotecan

50 mg/m\^2 IV

RADIATION

3D-CRT

RADIATION

IMRT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Manish Shah, MD · Weill Medical College of Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-12
Primary Completion
2018-08-01
Completion
2018-08-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485834 on ClinicalTrials.gov